Zura Bio Limited (NASDAQ:ZURA - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for Zura Bio in a note issued to investors on Monday, May 19th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings of ($0.20) per share for the quarter. HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Zura Bio's current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Zura Bio's Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.21) EPS and FY2026 earnings at ($0.82) EPS.
Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02).
A number of other equities analysts have also recently commented on the stock. Oppenheimer cut their target price on shares of Zura Bio from $19.00 to $17.00 and set an "outperform" rating on the stock in a report on Friday, May 9th. Chardan Capital cut their target price on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, March 26th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $15.00 target price on shares of Zura Bio in a report on Wednesday, March 26th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Zura Bio presently has an average rating of "Buy" and an average target price of $14.33.
Check Out Our Latest Report on ZURA
Zura Bio Trading Down 2.7%
Shares of NASDAQ:ZURA opened at $1.08 on Tuesday. The company has a market capitalization of $73.85 million, a PE ratio of -1.54 and a beta of 0.05. Zura Bio has a twelve month low of $0.97 and a twelve month high of $6.31. The firm has a 50 day simple moving average of $1.27 and a 200-day simple moving average of $1.93.
Institutional Investors Weigh In On Zura Bio
Several institutional investors and hedge funds have recently made changes to their positions in the business. ADAR1 Capital Management LLC boosted its position in shares of Zura Bio by 34.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 2,801,184 shares of the company's stock worth $3,614,000 after buying an additional 723,933 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Zura Bio by 12,060.8% in the 4th quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company's stock valued at $6,583,000 after purchasing an additional 2,611,532 shares in the last quarter. Allostery Investments LP lifted its holdings in Zura Bio by 44.2% in the 1st quarter. Allostery Investments LP now owns 2,329,384 shares of the company's stock valued at $3,005,000 after purchasing an additional 714,258 shares in the last quarter. Armistice Capital LLC lifted its holdings in Zura Bio by 2.4% in the 1st quarter. Armistice Capital LLC now owns 1,536,000 shares of the company's stock valued at $1,981,000 after purchasing an additional 36,000 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Zura Bio by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 955,426 shares of the company's stock valued at $2,389,000 after purchasing an additional 42,801 shares in the last quarter. 61.14% of the stock is currently owned by hedge funds and other institutional investors.
Zura Bio Company Profile
(
Get Free Report)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
